Market Research Report
Latin America, Middle East & Africa Genetic Testing Market (2019-2025)
|Latin America, Middle East & Africa Genetic Testing Market (2019-2025)|
Published: August 31, 2019
Content info: 90 Pages
Delivery time: 1-2 business days
The Latin America, Middle East and Africa Genetic Testing Market would witness market growth of 12.3% CAGR during the forecast period (2019-2025).
Carrier testing is used to detect individuals bearing a copy of a gene mutation that creates a genetic illness when present in two copies. This kind of tests is available for persons with a genetic disorder in family history and persons with an increased danger of specific genetic conditions in certain ethnic groups. The test can provide data about a couple's danger of a kid with a genetic disease if both parents are tested.
The increase in the incidence of genetic disorders and cancer plays an important role in the development of the genetic testing industry. In addition, an increase in personalized medicine therapy is anticipated in the coming years to increase the market growth. However, standardization disagreements about genetic test-based diagnostics and strict legislative requirements for product approvals are expected to hamper the development of the genetic testing market during the prediction period.
Based on Type, the market is segmented into Predictive and Presymptomatic Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, and Other Types. Based on Technology, the market is segmented into Cytogenetic Testing, Biochemical Testing and Molecular Testing. Based on Application, the market is segmented into Cancer Diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis and Other Applications. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Myriad Genetics, Inc., Empire Genomics LLC, Bio-Rad Laboratories, Inc., Novartis AG, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Illumina, Inc., Danaher Corporation, and Abbott Laboratories (Abbott Laboratories Molecular, Inc.).